ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1508

Simvastatin Attenuates Pulmonary Fibrosis in a Murine Model of Systemic Sclerosis

Gianluca Bagnato1, Alessandra Bitto2, Natasha Irrera2, Gabriele Pizzino2, Donatella Sangari1, Maurizio Cinquegrani3, Neal Roberts4, Gianfilippo Bagnato1, Francesco Squadrito2 and Antonino Saitta3, 1Rheumatology, University of Messina, Messina, Italy, 2Pharmacology, University of Messina, Messina, Italy, 3Internal Medicine, University of Messina, Messina, Italy, 4Medical College of Virginia, Richmond, VA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cutaneous manifestations, pulmonary complications, scleroderma and statins

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Simvastatin is best known for its antilipidemic action due to its inhibition of 3-hydroxy-3-methylglutaryl CoenzymeA (HMG CoA) reductase. Inhibition of biological precursors in this pathway also enables pleiotrophic immunomodulatory and anti-inflammatory capabilities. The antifibrotic effect of simvastatin has been shown in human lung fibroblasts. This study aimed to measure  beneficial effects of simvastatin, and to explore mechanisms of,  development of pulmonary fibrosis and skin thickening in a murine model of systemic sclerosis.

Methods: Chronic oxidant stress SSc was induced in BALB/c mice by daily subcutaneous injections of HOCl for 6 weeks as characterized in detail as the Cochin chronic oxidant stress model of SSc (Batteux F, Kavian N, Servettaz A. New insights on chemically induced animal models of systemic sclerosis.Curr Opin Rheumatol. 2011 Nov;23(6):511-8). Mice (n=24) were randomized in three arms: treatment with either simvastatin plus HOCl (n=9): vehicle plus HOCl (n=10), or vehicle alone (n=5). Statin treatment (40 mg/kg) was initiated 30 minutes after HOCl subcutaneous injection and continued daily for the 6 weeks. Skin and lung fibrosis were evaluated by histological methods. The severity of fibrosis was assessed using ordinal or nominal scales  in both tissues and the results compared nonparametrically

Results: Injections of HOCl induced cutaneous and lung fibrosis in BALB/c mice as demonstrated by routine histological analysis. Simvastatin treatment both reduced skin thickness by 55% (upper row of 3 representative photomicrographs) and attenuated the histopathological change of HOCl-induced pulmonary fibrosis as shown in the lower series.    .,

Conclusion: Simvastatin reduces the development of pulmonary fibrosis potentially modulating adverse lung parenchymal remodeling as shown by the reduced deposition of collagen in alveolar septae in this murine model. Simvastatin also reduces skin thickness in the model. The histological evidence from these  experiments suggests that—given the low, 1 per million death rate from statin prescriptions and the morbidity and mortality of SSC pulmonary disease—consideration of human  trials is warranted to determine the potential safety and efficacy of simvastatin for treatment of pulmonary fibrosis. 


Disclosure:

G. Bagnato,
None;

A. Bitto,
None;

N. Irrera,
None;

G. Pizzino,
None;

D. Sangari,
None;

M. Cinquegrani,
None;

N. Roberts,
None;

G. Bagnato,
None;

F. Squadrito,
None;

A. Saitta,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/simvastatin-attenuates-pulmonary-fibrosis-in-a-murine-model-of-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology